EuroBiotech: More Articles of Note


> Protalix BioTherapeutics talked up the prospect of filing for approval of PRX-102 in Fabry disease. The Israeli biotech is continuing to enroll patients in studies of the modified version of recombinant alpha-Galactosidase-A protein but thinks it already has enough subjects for a quickie approval. Release 

> Orchard Therapeutics’ IPO haul hit $225 million (€200 million) following the partial exercise of the underwriters’ option. Statement 

> Novo Nordisk entered into a research collaboration with Embark Biotech. The Danish compatriots will work to discover treatments for obesity and metabolic disease. Release

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.

> Acacia Pharma re-filed for approval of Barhemsys. Statement 

> Onxeo posted phase 1 data on its DNA damage response inhibitor. The data tee Onxeo up to expand its clinical program next year. Release 

> Acesion Pharma committed to initiating a phase 2 trial of cardioversion therapy AP30663 next year. The Danish biotech outlined the plans after posting phase 1 data on the atrial fibrillation drug. Statement